Skip to main
DBD
DBD logo

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf is expected to see a sequential and year-over-year increase in Retail sales, particularly in Europe, throughout the latter half of the year, indicating strong market demand and growth potential. The company is also projected to achieve nearly double its current free cash flow (FCF), with an estimated $205 million by 2025, reinforcing its financial stability. Additionally, Diebold Nixdorf's balance sheet and liquidity are reportedly in the best condition in recent history, with improvements in FCF conversion expected, contributing to a favorable outlook for investors.

Bears say

Diebold Nixdorf Inc faces several fundamental risks that contribute to a negative outlook, including potential challenges in offsetting tariff-related costs and the adverse effects of a volatile trade environment, which may not be adequately reflected in current forecasts. Additionally, the company may experience disruptions in product shipments and service installations due to ongoing supply chain issues and the lingering impacts of the COVID-19 pandemic. Furthermore, lower-than-expected upgrade and replacement activity, combined with transaction volatility in the company's Banking vertical, alongside currency fluctuations, raises concerns about the overall stability and performance of Diebold Nixdorf's financial outlook.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.